Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Active not recruiting 2Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 2Thoracic 1Sarcoma 1Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Gliosarcoma 1

Interventions

Radiotherapy 144Doxorubicin 112Temozolomide 110Cyclophosphamide 110Filgrastim 79Ifosfamide 70Imatinib Mesylate 69Etoposide 69Bevacizumab 55Vincristine 51Gemcitabine 50Peripheral Blood Stem Cell Transplantation 47Irinotecan 43Methotrexate 39Cisplatin 36Carboplatin 36Radiation 35fludarabine phosphate 34Busulfan 34pazopanib 32Sirolimus 30Melphalan 30Trabectedin 29Docetaxel 27Chemotherapy, Adjuvant 27Cyclosporine 25Carmustine 25sargramostim 24Surgical Procedures, Operative 23Sunitinib 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Contrast Media × Sarcoma × Clear all
NCT04396860 2026-04-22

Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma

National Cancer Institute (NCI)

Phase 2/3 Completed
159 enrolled 17 charts
Sarcoma

Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡